Apimeds Pharmaceuticals US (APUS) Cash from Investing Activities (2025)

Apimeds Pharmaceuticals US (APUS) reported Cash from Investing Activities of -$10.0 million for Q4 2025, down 44374.01% quarter-over-quarter from -$22540.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Cash from Investing Activities (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Cash from Investing Activities for 1 years, with the latest figure at -$10.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 229.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -87.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 743.70 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -506.20 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -60.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -2.08 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -15.45 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 25.99 Mn
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - -10.02 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -10.02 Mn
Dec 31, 2025 -10.02 Mn
Sep 30, 2025 -22,540.00
Sep 30, 2025 -22,540.00